Sanofi ditches an Ascendis project; Bristol-Myers' PD-1 treatment aces another cancer study;

@FierceBiotech: EuroBiotech Report: Israel awaits $250M fund, ThromboGenics spins out oncology asset, MolMed licenses CAR-T. More | Follow @FierceBiotech

@JohnCFierce: Trending: The flimsy case for a miracle ALS drug collapses under expert scrutiny. Editor's corner | Follow @JohnCFierce

> Sanofi ($SNY) is walking away from an insulin project with Ascendis Pharma ($ASND), a decision the company said was unrelated to its platform technology. The two are still working together on a peptide collaboration. More

> Bristol-Myers Squibb's ($BMY) PD-1-blocking Opdivo charted more positive results in lung cancer, meeting its goals and leading investigators to stop the trial early. News

> French biotech MedDay says its biotin-based treatment for multiple sclerosis met its main goal in a Phase III trial. Item

Medical Device News

@FierceMedDev: ICYMI: PatientsLikeMe and Biogen reveal positive data from wearable device study for MS. Report | Follow @FierceMedDev

@VarunSaxena2: Alcon intraocular lens gets FDA's stringent PMA approval. News | Follow @VarunSaxena2

@EmilyWFierce: Focus Diagnostics gets FDA nod for rapid strep test. FierceDiagnostics article | Follow @EmilyWFierce

> EndoGastric skips toward positive study review for GERD device. More

> Q1 med tech venture dips to lowest since 2013--but med tech IPOs outpace biotech. Report

Pharma News

@FiercePharma: GlaxoSmithKline to close Pittsburgh office, consolidate consumer ops in New Jersey. News | Follow @FiercePharma

@EricPFierce: Sanofi Pasteur is adding a fill/finish facility at US site as part of dengue vax plan. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AbbVie moves closer to Japan's crowded hep C field with priority review nod. Article | Follow @CarlyHFierce

> Analyst: Vivus generic threats a positive for obesity market. More

> Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch? News

> BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly. Article